MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.

Merck KGaA's experimental multiple sclerosis (MS) drug missed the primary goal in highly anticipated late-stage trials, dealing a major blow to the German company's growth ambitions and hitting ...

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme ...

Merck KGaA’s shares fell around 13% after its multiple sclerosis drug evobrutinib didn’t meet a key goal in late-stage trials. ... Merck MS Drug Fails to Meet Target of Late-Stage Trials. Share.

Merck, a leading science and technology company, today announced that data for approved and investigational multiple sclerosis (MS) treatments, MAVENCLAD ® (Cladribine Tablets) and Rebif ...

Merck in Neurology and Immunology Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS).

Merck KGaA’s highly anticipated experimental multiple sclerosis (MS) drug failed to meet its primary endpoint in two Phase 3 trials, the company announced this week. The EVOLUTION trials found that ...

Merck, seen as leading the race to win approval for a more targeted type of MS drug, said in April that U.S. regulators had paused enrolment of new patients into a trial testing the drug ...

Merck, a leading science and technology company, today announced that its two Phase III EVOLUTION clinical trials ... The relapsing forms of MS are the most common. Merck in Neurology and Immunology.

Merck KGaA has finally claimed an FDA approval for its oral MS therapy Mavenclad, eight years after being turned down by the US regulator.

German drugmaker Merck Serono is one step closer to releasing the first pill to treat multiple sclerosis, the company said Friday. In a press statement, Merck said that patients taking cladribine ...